BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24133627)

  • 1. Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
    Ishikawa H; Wakabayashi K; Suzuki S; Mutoh M; Hirata K; Nakamura T; Takeyama I; Kawano A; Gondo N; Abe T; Tokudome S; Goto C; Matsuura N; Sakai T
    Cancer Med; 2013 Feb; 2(1):50-6. PubMed ID: 24133627
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemoprevention with low-dose aspirin, mesalazine, or both in patients with familial adenomatous polyposis without previous colectomy (J-FAPP Study IV): a multicentre, double-blind, randomised, two-by-two factorial design trial.
    Ishikawa H; Mutoh M; Sato Y; Doyama H; Tajika M; Tanaka S; Horimatsu T; Takeuchi Y; Kashida H; Tashiro J; Ezoe Y; Nakajima T; Ikematsu H; Hori S; Suzuki S; Otani T; Takayama T; Ohda Y; Mure K; Wakabayashi K; Sakai T
    Lancet Gastroenterol Hepatol; 2021 Jun; 6(6):474-481. PubMed ID: 33812492
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of colorectal cancer: systematic review and economic evaluation.
    Cooper K; Squires H; Carroll C; Papaioannou D; Booth A; Logan RF; Maguire C; Hind D; Tappenden P
    Health Technol Assess; 2010 Jun; 14(32):1-206. PubMed ID: 20594533
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of eicosapentaenoic acid and/or aspirin for colorectal adenoma prevention during colonoscopic surveillance in the NHS Bowel Cancer Screening Programme (The seAFOod Polyp Prevention Trial): study protocol for a randomized controlled trial.
    Hull MA; Sandell AC; Montgomery AA; Logan RF; Clifford GM; Rees CJ; Loadman PM; Whitham D
    Trials; 2013 Jul; 14():237. PubMed ID: 23895505
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eicosapentaenoic acid and aspirin, alone and in combination, for the prevention of colorectal adenomas (seAFOod Polyp Prevention trial): a multicentre, randomised, double-blind, placebo-controlled, 2 × 2 factorial trial.
    Hull MA; Sprange K; Hepburn T; Tan W; Shafayat A; Rees CJ; Clifford G; Logan RF; Loadman PM; Williams EA; Whitham D; Montgomery AA;
    Lancet; 2018 Dec; 392(10164):2583-2594. PubMed ID: 30466866
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non steroidal anti-inflammatory drugs (NSAID) and Aspirin for preventing colorectal adenomas and carcinomas.
    Asano TK; McLeod RS
    Cochrane Database Syst Rev; 2004; 2004(2):CD004079. PubMed ID: 15106236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials.
    Cole BF; Logan RF; Halabi S; Benamouzig R; Sandler RS; Grainge MJ; Chaussade S; Baron JA
    J Natl Cancer Inst; 2009 Feb; 101(4):256-66. PubMed ID: 19211452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.
    Ishikawa H; Mutoh M; Suzuki S; Tokudome S; Saida Y; Abe T; Okamura S; Tajika M; Joh T; Tanaka S; Kudo SE; Matsuda T; Iimuro M; Yukawa T; Takayama T; Sato Y; Lee K; Kitamura S; Mizuno M; Sano Y; Gondo N; Sugimoto K; Kusunoki M; Goto C; Matsuura N; Sakai T; Wakabayashi K
    Gut; 2014 Nov; 63(11):1755-9. PubMed ID: 24488498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genetics, inheritance and strategies for prevention in populations at high risk of colorectal cancer (CRC).
    Burn J; Mathers J; Bishop DT
    Recent Results Cancer Res; 2013; 191():157-83. PubMed ID: 22893205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical management of adenomatous polyposis in patients with hereditary non-polyposis colorectal cancer and familial adenomatous polyposis].
    Sheng JQ; Li SR; Yang XY; Zhang YH; Su H; Yu DL; Yan W; Geng HG
    Zhonghua Yi Xue Za Zhi; 2006 Feb; 86(8):526-9. PubMed ID: 16681880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Utility of Mesalazine in Familial Adenomatous Polyposis: Clinical Report of Reduction of Polyp Size in Patients with Ulcerative Colitis, and Safety Examination in Familial Adenomatous Polyposis Patients.
    Ishikawa H; Mutoh M; Abe T; Nakajima T; Takeuchi Y; Ezoe Y; Wakabayashi K; Doyama H; Sakai T
    Pharmacology; 2019; 104(1-2):51-56. PubMed ID: 31067545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell proliferation and apoptotic indices predict adenoma regression in a placebo-controlled trial of celecoxib in familial adenomatous polyposis patients.
    Sinicrope FA; Half E; Morris JS; Lynch PM; Morrow JD; Levin B; Hawk ET; Cohen DS; Ayers GD; Stephens LC;
    Cancer Epidemiol Biomarkers Prev; 2004 Jun; 13(6):920-7. PubMed ID: 15184247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
    Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
    BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis: Secondary Analysis of a Randomized Clinical Trial.
    Samadder NJ; Kuwada SK; Boucher KM; Byrne K; Kanth P; Samowitz W; Jones D; Tavtigian SV; Westover M; Berry T; Jasperson K; Pappas L; Smith L; Sample D; Burt RW; Neklason DW
    JAMA Oncol; 2018 May; 4(5):671-677. PubMed ID: 29423501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonsteroidal anti-inflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study.
    Grau MV; Sandler RS; McKeown-Eyssen G; Bresalier RS; Haile RW; Barry EL; Ahnen DJ; Gui J; Summers RW; Baron JA
    J Natl Cancer Inst; 2009 Feb; 101(4):267-76. PubMed ID: 19211442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Celecoxib for the prevention of colorectal adenomatous polyps.
    Arber N; Eagle CJ; Spicak J; Rácz I; Dite P; Hajer J; Zavoral M; Lechuga MJ; Gerletti P; Tang J; Rosenstein RB; Macdonald K; Bhadra P; Fowler R; Wittes J; Zauber AG; Solomon SD; Levin B;
    N Engl J Med; 2006 Aug; 355(9):885-95. PubMed ID: 16943401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin and other nonsteroidal anti-inflammatory agents in the prevention of colorectal cancer.
    Sandler RS
    Important Adv Oncol; 1996; ():123-37. PubMed ID: 8791132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The safety and efficacy of celecoxib in children with familial adenomatous polyposis.
    Lynch PM; Ayers GD; Hawk E; Richmond E; Eagle C; Woloj M; Church J; Hasson H; Patterson S; Half E; Burke CA
    Am J Gastroenterol; 2010 Jun; 105(6):1437-43. PubMed ID: 20234350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention by daily soluble aspirin of colorectal adenoma recurrence: 4-year results of the APACC randomised trial.
    Benamouzig R; Uzzan B; Deyra J; Martin A; Girard B; Little J; Chaussade S;
    Gut; 2012 Feb; 61(2):255-61. PubMed ID: 21890814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aspirin and gastrointestinal cancer.
    Thun MJ
    Adv Exp Med Biol; 1997; 400A():395-402. PubMed ID: 9547582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.